PDF(Pubmed)
Abstract：
UNASSIGNED: Recent studies suggest that gut microbiota composition, abundance and diversity can influence many chronic diseases such as type 2 diabetes. Modulating gut microbiota through targeted nutrition can provide beneficial effects leading to the concept of personalized nutrition for health improvement. In this prospective clinical trial, we evaluated the impact of a microbiome-based targeted personalized diet on hyperglycaemic and hyperlipidaemic individuals. Specifically, BugSpeaks®-a microbiome profile test that profiles microbiota using next generation sequencing and provides personalized nutritional recommendation based on the individual microbiota profile was evaluated.
UNASSIGNED: A total of 30 participants with type 2 diabetes and hyperlipidaemia were recruited for this study. The microbiome profile of the 15 participants (test arm) was evaluated using whole genome shotgun metagenomics and personalized nutritional recommendations based on their microbiota profile were provided. The remaining 15 participants (control arm) were provided with diabetic nutritional guidance for 3 months. Clinical and anthropometric parameters such as HbA1c, systolic/diastolic pressure, c-reactive protein levels and microbiota composition were measured and compared during the study.
UNASSIGNED: The test arm (microbiome-based nutrition) showed a statistically significant decrease in HbA1c level from 8.30 (95% confidence interval (CI), [7.74-8.85]) to 6.67 (95% CI [6.2-7.05]), p < 0.001 after 90 days. The test arm also showed a 5% decline in the systolic pressure whereas the control arm showed a 7% increase. Incidentally, a sub-cohort of the test arm of patients with >130 mm Hg systolic pressure showed a statistically significant decrease of systolic pressure by 14%. Interestingly, CRP level was also found to drop by 19.5%. Alpha diversity measures showed a significant increase in Shannon diversity measure (p < 0.05), after the microbiome-based personalized dietary intervention. The intervention led to a minimum two-fold (Log2 fold change increase in species like Phascolarctobacterium succinatutens, Bifidobacterium angulatum, and Levilactobacillus brevis which might have a beneficial role in the current context and a similar decrease in species like Alistipes finegoldii, and Sutterella faecalis which have been earlier shown to have some negative effects in the host. Overall, the study indicated a net positive impact of the microbiota based personalized dietary regime on the gut microbiome and correlated clinical parameters.
UNASSIGNED: A total of 30 participants with type 2 diabetes and hyperlipidaemia were recruited for this study. The microbiome profile of the 15 participants (test arm) was evaluated using whole genome shotgun metagenomics and personalized nutritional recommendations based on their microbiota profile were provided. The remaining 15 participants (control arm) were provided with diabetic nutritional guidance for 3 months. Clinical and anthropometric parameters such as HbA1c, systolic/diastolic pressure, c-reactive protein levels and microbiota composition were measured and compared during the study.
UNASSIGNED: The test arm (microbiome-based nutrition) showed a statistically significant decrease in HbA1c level from 8.30 (95% confidence interval (CI), [7.74-8.85]) to 6.67 (95% CI [6.2-7.05]), p < 0.001 after 90 days. The test arm also showed a 5% decline in the systolic pressure whereas the control arm showed a 7% increase. Incidentally, a sub-cohort of the test arm of patients with >130 mm Hg systolic pressure showed a statistically significant decrease of systolic pressure by 14%. Interestingly, CRP level was also found to drop by 19.5%. Alpha diversity measures showed a significant increase in Shannon diversity measure (p < 0.05), after the microbiome-based personalized dietary intervention. The intervention led to a minimum two-fold (Log2 fold change increase in species like Phascolarctobacterium succinatutens, Bifidobacterium angulatum, and Levilactobacillus brevis which might have a beneficial role in the current context and a similar decrease in species like Alistipes finegoldii, and Sutterella faecalis which have been earlier shown to have some negative effects in the host. Overall, the study indicated a net positive impact of the microbiota based personalized dietary regime on the gut microbiome and correlated clinical parameters.
摘要：
■最近的研究表明，肠道菌群组成，丰富和多样性可以影响许多慢性疾病，如2型糖尿病。通过靶向营养调节肠道微生物群可以提供有益效果，从而产生个性化营养的概念，以改善健康。在这项前瞻性临床试验中,我们评估了基于微生物组的针对性个性化饮食对高血糖和高脂血症个体的影响.具体来说,BugSpeaks®-一种微生物组谱测试,其使用下一代测序来描绘微生物群,并基于个体微生物区谱来提供个性化营养推荐。
■本研究共招募了30名2型糖尿病和高脂血症患者。使用全基因组鸟枪宏基因组学评估了15名参与者（测试臂）的微生物组谱，并提供了基于其微生物区谱的个性化营养建议。其余15名参与者（对照组）接受3个月的糖尿病营养指导。临床和人体测量参数，如HbA1c，收缩压/舒张压，在研究过程中测量并比较了c反应蛋白水平和微生物群组成。
■测试组（基于微生物组的营养）显示HbA1c水平从8.30（95％置信区间（CI），[7.74-8.85])至6.67(95%CI[6.2-7.05])，90天后p<0.001。测试臂还显示收缩压下降5％，而对照臂显示增加7％。顺便说一句,收缩压>130mmHg患者的试验组的一个子队列显示收缩压显著下降14%.有趣的是,CRP水平也下降了19.5%。Alpha多样性测度显示Shannon多样性测度显著增加(p<0.05),在基于微生物组的个性化饮食干预后。干预导致了最少的两倍（丁香杆菌等物种的Log2倍变化增加，成角双歧杆菌，和短左杆菌，在当前情况下可能具有有益的作用，并且在诸如Alistipesfinegoldii之类的物种中也有类似的减少，和粪梭菌，先前已被证明对宿主有一些负面影响。总的来说,该研究表明，基于微生物群的个性化饮食方案对肠道微生物组和相关临床参数的净积极影响。
■本研究共招募了30名2型糖尿病和高脂血症患者。使用全基因组鸟枪宏基因组学评估了15名参与者（测试臂）的微生物组谱，并提供了基于其微生物区谱的个性化营养建议。其余15名参与者（对照组）接受3个月的糖尿病营养指导。临床和人体测量参数，如HbA1c，收缩压/舒张压，在研究过程中测量并比较了c反应蛋白水平和微生物群组成。
■测试组（基于微生物组的营养）显示HbA1c水平从8.30（95％置信区间（CI），[7.74-8.85])至6.67(95%CI[6.2-7.05])，90天后p<0.001。测试臂还显示收缩压下降5％，而对照臂显示增加7％。顺便说一句,收缩压>130mmHg患者的试验组的一个子队列显示收缩压显著下降14%.有趣的是,CRP水平也下降了19.5%。Alpha多样性测度显示Shannon多样性测度显著增加(p<0.05),在基于微生物组的个性化饮食干预后。干预导致了最少的两倍（丁香杆菌等物种的Log2倍变化增加，成角双歧杆菌，和短左杆菌，在当前情况下可能具有有益的作用，并且在诸如Alistipesfinegoldii之类的物种中也有类似的减少，和粪梭菌，先前已被证明对宿主有一些负面影响。总的来说,该研究表明，基于微生物群的个性化饮食方案对肠道微生物组和相关临床参数的净积极影响。
